Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601
2015 ASTRO Annual MeetingHoward M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).
Related Videos
Catherine C. Park, MD, on Novel Clinical Paradigms
Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, ...
Bridgett Harr, CNP, on Reducing ER Visits and Admissions in High-Risk Head and Neck Cancer Patients
Bridgett Harr, CNP, of Cleveland Clinic, discusses the advanced practice nurse follow-up clinic, which focuses on symptom management in the first 90 days postchemoradiation (Abstra...
Howard M. Sandler, MD, on Prostate Cancer: Results From RTOG 0415
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses this phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer...
James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer
James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk pros...
Brian D. Kavanagh, MD, on Improving Value and Elevating the Patient Care Experience
Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided i...
